dc.contributorhttps://orcid.org/0000-0002-3403-9849
dc.creatorHerrera Esparza, Rafael
dc.creatorAvalos Díaz, Esperanza del Refugio
dc.date.accessioned2020-12-10T05:26:17Z
dc.date.available2020-12-10T05:26:17Z
dc.date.created2020-12-10T05:26:17Z
dc.date.issued2015
dc.identifier2320-7221
dc.identifierhttp://ricaxcan.uaz.edu.mx/jspui/handle/20.500.11845/2187
dc.identifierhttps://doi.org/10.48779/hhg6-2s04
dc.description.abstractMaternal antinuclear antibodies with anti-Ro or anti-La specificity might be pathogenic to the fetus and could induce molecular neonatal pathologies, such as neonatal lupus (NL) with or without congenital heart block (CHB). The cutaneous manifestations of neonatal lupus appear at birth or a few weeks later, and skin lesions may persist for weeks. While CHB is characterized by intrauterine bradycardia or low heart rates at birth and may persist for months, depending on the degree of blockage. Clinical and experimental data demonstrated that anti-Ro and anti-La autoantibodies functionally inhibit L-type calcium channels and induce abnormalities in electrical conduction of the cardiac myocytes. It has been 38 years since the first clinical description of CHB. Presently, the pathophysiology of CHB has been clarified through clinical and basic research studies
dc.languageeng
dc.publisherChanRe Journals
dc.relationgeneralPublic
dc.relationhttps://www.chanrejournals.com/index.php/rheumatology/search/results
dc.rightshttp://creativecommons.org/licenses/by-nc-sa/3.0/us/
dc.rightsAtribución-NoComercial-CompartirIgual 3.0 Estados Unidos de América
dc.sourceInternet Journal of Rheumatology and Clinical Immunology Vol. 3, No. 1, pp.1-6
dc.titleNeonatal molecular pathologies induced by maternal anti-Ro and anti-La antibodies
dc.typeinfo:eu-repo/semantics/article


Este ítem pertenece a la siguiente institución